Gts Securities LLC Geron Corp Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$4.17 - $4.99 $236,439 - $282,933	-56,700 Reduced 62.17%	34,500 $156,000
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $42,470 - $69,733	13,700 Added 17.68%	91,200 $386,000
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $33,075 - $65,016	18,900 Added 32.25%	77,500 $255,000
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $24,186 - $32,109	13,900 Added 31.1%	58,600 $123,000
Q3 2023 Nov 15, 2023	BUY	$2.11 - $3.28 $94,317 - $146,616	44,700 New	44,700 $94,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.53B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.